Bird flu cases are rising again. How bad is it this time?
What causes bird flu, and what are the symptoms?
Bird flu is caused by influenza viruses that occur naturally in wild aquatic birds worldwide. These viruses can spread to domestic poultry and other animals.
In birds, symptoms include sudden death, lethargy, reduced appetite and egg production, swelling of the head, and respiratory or digestive issues.
Though rare, human infections can occur through close contact with infected birds or contaminated surfaces, typically via droppings. Human symptoms range from mild fever and cough to severe respiratory illness.
India's bird flu situation and the concerns
As of 24 July 2025, India has reported 41 cases of avian influenza in domestic poultry across 10 states: Maharashtra, Chhattisgarh, Jharkhand, Andhra Pradesh, Madhya Pradesh, Telangana, Karnataka, Bihar, Uttar Pradesh, and Odisha, according to minister of state for fisheries, and animal husbandry S.P. Singh Baghel.
A worrying new trend is the detection of the virus in atypical hosts such as tigers, lions, leopards, and domestic cats, raising concerns that the virus may be adapting to new species. While the risk to humans remains low, this cross-species transmission underscores the need for continued vigilance.
Historical trend of avian influenza outbreaks in India
India saw its worst year in 2021, with 118 bird flu outbreaks. Cases fell sharply in the following years—22 in 2022 and 15 in 2023—before rising again to 49 in 2024.
India has reported 41 outbreaks so far in 2025. While numbers remain below the 2021 peak, the resurgence is prompting renewed attention.
What steps are being taken by India?
India has rolled out a series of measures to contain bird flu outbreaks:
Is a vaccine available in India?
Yes. India has approved an indigenous low-pathogenic avian influenza (H9N2) vaccine developed by the ICAR-National Institute of High Security Animal Diseases, Bhopal.
The technology was transferred to Indian private companies starting in late 2022, with products becoming available in early 2025. This vaccination is part of India's strategy to manage and prevent the disease and reduce economic losses.
What's the global status of H5N1 avian influenza in 2025?
Avian Influenza remains a global concern.
Europe: Persistent outbreaks in wild and domestic birds; unusual detections in sheep, as per European Centre for Disease Prevention and Control and Norwegian Veterinary Institute
The Americas: Ongoing cases in poultry and wild birds; the virus has also infected dairy cattle in the US, leading to 41 human cases as of July 2025, as per Centre for Disease Control and Prevention, US.
Asia: Cambodia has reported multiple human H5N1 cases, totalling 14 by late July, according to the World Health Organisation (WHO).
The increasing spillover to mammals, including livestock, signals a shift in the virus's behaviour and demands stronger global coordination.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
8 important health and reproductive tests for women aged 27–35
If you're between 27 and 35 born anytime from 1990 to 1997, you're in a phase where your body might look fine on the outside but be shifting in ways you can't see. According to Dr Anamika Raghuvanshi, a naturopath, nutritionist, and lifestyle educator, this is the perfect time to take your health seriously, not just for the now, but for the future too. In an Instagram post shared on July 28, she laid out a smart, simple checklist of tests that every woman in this age group should consider, even if you feel perfectly healthy. These tests aren't just about fertility. They also track your energy, hormones, immunity, and risk of long-term lifestyle diseases. Don't skip these screenings, they can reveal silent issues before symptoms even show. Know what tests to get, why they matter in your late 20s and early 30s, and what they reveal. Here's what made it to her must-check list and why. 8 essential health tests every woman should consider from 27-35 Complete blood count (CBC) This is your health report card in a single test. A CBC measures red and white blood cell levels, haemoglobin, and platelets and can detect signs of anemia, infection, inflammation, or low immunity before they manifest physically. If you're always tired, catch colds easily, or feel unusually cold, this test can help explain why. It's a great starting point if you haven't had any recent blood work. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo Thyroid profile (T3, T4, TSH) Your thyroid quietly controls everything from your energy, mood, metabolism, fertility, to skin and heart health. This panel checks if your thyroid hormones are in balance. If your periods are irregular, you're gaining weight despite eating well, or you feel anxious or sluggish, it might be a thyroid issue. Imbalances can also mimic or worsen PCOS and depression. Every woman should get this checked at least once every few years. Vitamin D and B12 levels Deficiencies in Vitamin D and B12 are widespread in Indian women , even among those who eat well. Low levels can cause chronic fatigue, brain fog, anxiety, muscle pain, hair loss, and even mood swings. These nutrients are crucial for nervous system function, bone density, immunity, and hormonal health. If left untreated, they can impact everything from your menstrual cycle to your mental wellbeing. A quick blood test reveals if supplementation is needed. Reproductive hormone panel (AMH, LH, FSH, Prolactin) Even if you're not trying to conceive right now, these markers give insight into your ovarian reserve, egg quality, and hormonal rhythm. They can help detect early signs of PCOS, premature ovarian ageing, hypothalamic dysfunction, or prolactin issues that may affect fertility later. Understanding your reproductive health now can help you make more informed decisions in the future, from contraception to planning a family. Pelvic ultrasound (abdominal or transvaginal) A painless scan that reveals what blood tests can't. It checks your uterus, ovaries, and pelvic structures for conditions like fibroids, ovarian cysts, PCOS, or endometriosis, which can affect your periods, pain levels, fertility, and long-term reproductive health. It's especially recommended if you have painful or irregular periods, sudden weight gain, or family history of uterine issues. It gives clarity, even if you're symptom-free. Pap smear and HPV test Cervical cancer is one of the most preventable cancers, if caught early. A pap smear detects abnormal cells on the cervix, while the HPV test looks for the virus strains most likely to cause cancer. Together, they're a powerful screening tool. Experts recommend getting both done by your mid-to-late 20s and repeating every 3–5 years. It's quick, often painless, and a huge step in safeguarding your future health. Blood sugar and lipid profile We often think of diabetes or heart disease as problems of old age, but insulin resistance and high cholesterol can quietly develop in your 20s, especially if you lead a sedentary life, have a stressful job, or poor sleep habits. These tests measure fasting blood glucose, HbA1c, LDL/HDL cholesterol, and triglycerides, helping you identify early warning signs and take action through diet, exercise, and lifestyle before things get serious. STD panel Sexually transmitted infections aren't always obvious and untreated STDs can cause fertility issues, chronic pain, and long-term reproductive damage. Regular screenings for HIV, hepatitis B and C, chlamydia, syphilis, and gonorrhoea are vital, especially if you're sexually active or planning pregnancy. Dr Raghuvanshi notes that these tests are non-negotiable for women's reproductive safety and long-term wellness. Don't wait for symptoms to appear; silence doesn't mean safety. Whether you're focusing on your career, your body, or planning a baby, these tests can help you stay in control of your health. 'By your late 20s and early 30s, your body's internal rhythm starts shifting, so now is the time to stay informed, not wait for symptoms,' she shared in her Instagram post. Preventive testing isn't about fear, it's about freedom, clarity, and self-care. Do it for your future energy, confidence, and peace of mind. Also read| Vaccination gaps spark resurgence in measles and whooping cough: Global warning
Hindustan Times
2 hours ago
- Hindustan Times
Nutrition coach shares 3 breakfast mistakes that can slow down weight loss: ‘Not eating enough protein'
Luisana Carrero is a nutrition coach who keeps sharing valuable insights on weight loss, diet and healthy living on her Instagram profile on a regular basis. From sharing healthy diet hacks to mistakes that we make in our daily eating habits that can slow down our metabolism, Luisana shares it all. Most of her content is also focused on tips and hacks for faster weight loss, and how to drop the extra kilos faster. Also read | Woman who lost 17 kg reveals these 3 high protein Indian vegetarian breakfast recipes helped her drastic weight loss Breakfast mistakes that women often make, which makes it more difficult for them to melt body fat.(Pexels) On August 5, Luisana shared an Instagram post explaining the breakfast mistakes that women often make, which makes it more difficult for them to melt body fat. 'As a fitness and nutrition coach, here are the 3 breakfast mistakes most women make that are holding them back from losing fat,' she added. Mistake 1: Only eating fruit While fruit is full of vitamins and fiber, eating it by itself can spike blood sugar, especially in the morning when your body is more sensitive to carbs. This can lead to cravings and a crash a few hours later. Instead: Pair fruit with protein and fat to balance blood sugar. Apple slices + almond butter + hard-boiled eggs Berries + cottage cheese or Greek yogurt Mistake 2: Not eating enough protein Low protein leads to less satiety, more cravings, and muscle loss over time (especially during a fat loss phase). Protein is key for appetite control, muscle retention and metabolism support. Instead: Aim for at least 20-30g protein in the morning. Mistake 3: Relying on healthy smoothies from cafés Many store-bought or café smoothies, bars, or bowls are marketed as healthy but are loaded with sugar, low in protein, extremely high in calories (some smoothies have 600+ calories). Also read | Trying to lose weight? Dietician says, avoid these five breakfast options Instead: Make your own smoothie at home where you can control what goes in. Focus on a good protein source (protein powder, Greek yogurt), healthy fats (nut butter, chia seeds) and fiber-rich carbs (berries, oats, spinach). Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Mint
2 hours ago
- Mint
These stocks are up more than 30% in 2025. They may still be undervalued.
It's been a roller-coaster year for Indian equities. Corporate earnings have been largely muted owing to a slowdown in demand, which has weighed on investor sentiment. Global macroeconomic uncertainties, from renewed trade tensions to tariff-related jitters, have given them more reasons to be cautious. But beneath the surface, a few stocks have staged powerful rallies fueled by strong earnings momentum, strategic expansion plans, and improving fundamentals. What makes these stocks particularly interesting is that they haven't just surged more than 30% so far this year but that they're still trading around 20% below their 52-week highs. In other words, despite strong rallies, they may still have room to run up further. If you've been sitting on the sidelines, looking for a big opportunity in this cautious market, here are three stocks that are worth a look. #1 Narayana Hrudayalaya Shares of the company are up 40% in 2025, yet 28% below their 52-week high of ₹2,372. The stock has been on an upswing over the past few months for various reasons: growing capacities, diversifying into other fields, and improving operational efficiency. Earlier in the year the company announced plans to add 1,535 beds by FY29, with a focus on strengthening its presence in existing locations: Bengaluru, Kolkata and Raipur. It outlined a capex outlay of about ₹750 crore over the next three to four years, of which ₹300 crore will be used for routine maintenance and increasing capacity at existing facilities, while ₹450 crore will be earmarked for greenfield and brownfield expansions. The company has also diversified into insurance services, aiming to improve healthcare access for the working class and poor. It has invested ₹1,000 crore in this vertical and plans to scale it up further depending on the initial outcomes. It is also eyeing aggressive growth in the primary healthcare segment, with plans to set up 50 clinics over the next year. Narayana Hrudayalaya's robust financials continue to underpin its expansion strategy. Over the past five years the company has delivered a steady 12% compound annual growth rate (CAGR) in revenue, driven by higher realisations, and an impressive 44% CAGR in net profit, reflecting its focus on operational efficiency and sustainable growth. Operating profit margins have followed suit, increasing steadily from 10.3% in 2019 to 23% in 2025. This has resulted in healthy return ratios for the company. The three-year average return on equity (RoE) stands at 28.8% while the return on capital employed (RoCE) stands at 25.1%. Despite this robust performance, shares of the company have declined 8.4% over the past month, following a minor dip in net profit for the June quarter. This has led to a slight valuation reset, with the stock now trading at a price-to-earnings ratio of 47.6, below its 10-year average of 50.2. FIIs, however, increased their stake in the company from 9.66% in March to 10.46% in June after four consecutive quarters of decline. This rebound could indicate renewed confidence in the company, possibly driven by improved earnings visibility, expansion plans, or a more attractive valuation after the correction. #2 Manorama Industries Manorama Industries is one of India's leading manufacturers of specialty fats and butters used in the chocolates, confectionery and cosmetics. The stock is up 38% in 2025 on account of its strong financial performance over the past two quarters, yet 18% below its 52-week high. It has consistently generated returns over the past year, boasting a remarkable increase of 114%, significantly outpacing the Sensex's 2.87% return. Over the past four quarters the company consistently improved its financial metrics with higher capacity utilisation, improved product mix, and sustained export demand. Revenue has grown steadily each quarter, from ₹133 crore in June 2024 to ₹195 crore in September 2024 and ₹290 crore in June 2025, likely driven by both volume gains and improved pricing power. Net profit grew from ₹14 crore in June 2024 to ₹51 crore by June 2025. The company has also managed to expand its operating profit margin from 20% to 27%, indicating strong operating leverage and improved cost-efficiency as revenue scaled. It aims for a top line of ₹1,050 crore in FY26, with 25-30% of the growth expected to come from higher volumes and another 5-10% from better price realisations. Revenue in FY25 stood at ₹771 crore. A recent ramping up of capacity is also expected to contribute to this growth. In the September quarter of 2024 the company commercialised a new 25,000-tonne fractionation facility, taking total capacity to 40,000 tons per annum. With capacity utilisation projected at 75-80% in FY26, the company expects to achieve greater operating efficiencies and cost optimisation. On the global front, Manorama has expanded its footprint through subsidiaries in West Africa, the UAE, and Brazil. The Latin American market, particularly Brazil, is seen as a major growth opportunity for its cocoa butter equivalent (CBE) and stearin products, with potential demand of 25,000-30,000 tonnes. The company remains focused on retaining existing customers while steadily adding new ones without compromising on margins or return on capital. Over the past five years revenue has grown at a CAGR of 33% while net profit has grown at 37%. Profitability metrics have remained healthy and stable, with a five-year average operating profit margin of 17.6% and an average net profit margin of 9.6%, reflecting strong cost control and consistent earnings quality. Return ratios have also held up well, with an RoE of 28% and an RoCE of 23%. While the stock has delivered strong returns over the past year, it has slipped 1% over the last month amid broader market volatility and trades 17% below its 52-week high. It has a PE ratio of 58.1, marginally below its 10-year average PE of 59.1, suggesting it may not be overheated despite the sharp run-up. #3 Blue Jet Healthcare Blue Jet Healthcare is a pharmaceutical and healthcare ingredient and intermediate company. It is the first manufacturer of saccharin and its salts (artificial sweeteners) in India. Blue Jet Healthcare's shares have climbed 36% in 2025, driven by improving growth prospects and renewed investor interest, but are currently 23.5% below their 52-week high. The stock is also up more than 100% since its listing in November 2023. While financial performance was subdued between FY20 and FY24, mainly owing to a lack of new product launches, the company saw a sharp turnaround in FY25, when revenue rose 45% to ₹1,030 crore from ₹712 crore in FY24, supported by strong demand across key segments. Net profit jumped 86% to ₹305 crore from ₹164 crore in the previous year, reflecting higher operating leverage. The company has also demonstrated strong capital efficiency, delivering an average RoE of 27% over the past three years. Its balance sheet remains conservative, with a debt-to-equity ratio of just 0.02. The stock has come under pressure recently, falling over 12% in the past month after the company reported a sharp sequential decline in profit and margins for the June 2025 quarter. Nevertheless, the company's performance remained strong on a year-on-year basis: revenue surged 118%, while net profit grew 141.3%, led by a strong ramp-up in pharmaceutical ingredients and active pharmaceutical ingredients. Management remains confident in its growth strategy, driven by capacity expansion, enhanced R&D capabilities, and a robust pipeline of high-value products. Blue Jet plans to add 1,000 kiloliters of capacity over the next 2-3 years through a newly acquired land parcel to be developed in three phases. This will support a range of products including APIs, with a focus on the API for bempedoic acid, as well as capacity additions for contrast media intermediates (CMI) and high-intensity sweeteners. The company is also deepening its R&D focus, allocating ₹40 crore to strengthening capabilities in amino acid derivatives and late-stage intermediates. It has built a robust pipeline of 20 high-interest opportunities, with around 30% (six candidates) already in the late phase 3 or commercial stage. Brokerage firm Motilal Oswal has a 'buy' rating on the stock with a target price of ₹1,100. The brokerage expects pharma intermediates and APIs to continue their robust growth momentum in FY26, supported by strong customer demand visibility and additional product launches. The stock appears attractively priced, currently trading at a PE of 38.1, below its historical average of 48.7. FIIs and DIIs have both reduced their stakes in the company, albeit marginally, from 2.28% to 1.97% and 1.33% to 0.95% over the past quarter. Even standout performers require research While the broader market has been relatively muted in 2025, these three stocks stand out for their strong financial performance, strategic growth initiatives, and improving investor sentiment. They've delivered solid returns despite broader volatility and still trade well below their 52-week highs, which makes them compelling stocks to watch. However, it's important to temper optimism with a dose of caution. Stocks that have corrected from their peaks may offer value, but can also remain under pressure if the company stumbled on execution or if market sentiment deteriorates further. As always, investors should do their own due diligence, align investments with their risk tolerance and financial goals, and avoid chasing momentum blindly. Past performance is not always indicative of future outcomes, and in a market such as this, prudent stock selection and patience often make the real difference. Ayesha Shetty is a research analyst registered with the Securities and Exchange Board of India. She is a certified financial risk manager (FRM) and is working toward her chartered financial analyst (CFA) designation. Disclosure: The author does not hold shares in any of the companies discussed. The views expressed are for informational purposes only and should not be considered investment advice. Readers should conduct their own research and consult a financial professional before making investment decisions.
